RT Journal Article
SR Electronic
T1 Significance of Pre-treatment Interferon-gamma Release in Patients With Non-small-cell Lung Cancer Receiving Immune Checkpoint Inhibitors
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 6971
OP 6978
DO 10.21873/anticanres.14721
VO 40
IS 12
A1 TOMONORI HIRASHIMA
A1 TOMOHIRO KANAI
A1 HIDEKAZU SUZUKI
A1 HIROKO YOSHIDA
A1 AKANE MATSUSITA
A1 HIROMI KAWASUMI
A1 SHINGO NASU
A1 AYAKO TANAKA
A1 NAOKO MORISHITA
A1 KUNIMITSU KAWAHARA
A1 YOSHITAKA TAMURA
A1 NORIO OKAMOTO
YR 2020
UL http://ar.iiarjournals.org/content/40/12/6971.abstract
AB Background/Aim: We retrospectively investigated the significance of pre-treatment interferon-gamma release (IGR) as a biomarker for predicting the efficacy of immune checkpoint inhibitor treatment (ICI-tx). Patients and Methods: This study included non-small-cell lung cancer patients who received ICI-tx between January 1, 2016 and April 30, 2019. IGR was measured using the positive control of an enzyme-linked immunosorbent assay. We defined the pre-treatment cut-off level of IGR as 10 IU/ml. Results: Fifty-four patients were divided into two groups; those with an IGR ≤10 IU/ml (lower group: LG) (n=15) and those with >10 IU/ml (higher group: HG) (n=39). The time to treatment failure (TTF) in the HG was significantly longer than that in the LG. In multivariate analyses, C-reactive protein and IGR levels were significant risk factors for TTF. Conclusion: Pre-treatment IGR level of >10 IU/ml is recommended to identify those patients who will respond favourably to ICI-tx.